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Abstract: Inherited neuromuscular disorders (INMD) are a heterogeneous group of rare diseases 
that involve muscles, motor neurons, peripheral nerves or the neuromuscular junction. Several dif-
ferent lab abnormalities have been linked to INMD: sometimes they are typical of the disorder, but 
they usually appear to be less specific. Sometimes serum biomarkers can point out abnormalities in 
presymtomatic or otherwise asymptomatic patients (e.g., carriers). More often a biomarker of INMD 
is evaluated by multiple clinicians other than expert in NMD before the diagnosis, because of the 
multisystemic involvement in INMD. The authors performed a literature search on biomarkers in 
inherited neuromuscular disorders to provide a practical approach to the diagnosis and the correct 
management of INMD. A considerable number of biomarkers have been reported that support the 
diagnosis of INMD, but the role of an expert clinician is crucial. Hence, the complete knowledge of 
such abnormalities can accelerate the diagnostic workup supporting the referral to specialists in 
neuromuscular disorders. 
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1. Background and Aims 
Inherited neuromuscular disorders (INMD) are rare diseases that involve muscles, 
motor neurons, peripheral nerves or the neuromuscular junction [1]. 
Even if the most important role in the diagnosis of INMD is played by clinical and 
subsequent examinations (e.g., neurophysiological, histo-morphological and genetic in-
vestigations), serum biomarkers may have a crucial role in the diagnosis and follow-up. 
Indeed, it is a well-known fact that serum biomarkers have a crucial role in the diag-
nosis of many acquired neuromuscular conditions ranging from autoimmune, inflamma-
tory and paraneoplastic diseases affecting the muscle and peripheral nerve [2–4], but their 
role appears to be less immediate and appreciated for INMD [1]. 
A particular mentioning for genetic investigations is worth in the diagnostic workup: 
indeed genetics is in rapid evolution and has radically modified the approach to rare dis-
eases in recent years [1,5,6]. In particular, the recent availability of next generation se-
quencing has deeply revolutioned the scenario of INMD, compared to only a few years 
ago, when the diagnostic algorithms were based on the sequencing gene by gene (e.g., 
Sanger), based on clinical, neurophysiology, biochemical and morphological evaluations 
[1]. In this scenario, serum biomarkers retain an important role in both the diagnosis and 
follow-up of INMD [7–10]. Many lab abnormalities commonly evaluated in routine blood 
examinations have been reported “typical” of certain INMD [8,11,12], but their role is 
sometimes underestimated in current clinical practice [13]. Moreover, lab samples are 
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usually cheap, easy-to-obtain and, in many circumstances, they are parts of other general 
clinical procedures. Conversely, some biomarkers are very unspecific (e.g., serum creatine 
kinase (CKO), but associated conditions may point out the underlining condition (e.g., 
concomitant factors; the entity and/or the persistence of the abnormalities) [8,14] or rule 
out other differential diagnoses [15]. Finally, in specific clinical conditions, some bi-
omarkers commonly used in clinical practice are indicative only if the sample is collected 
in a specific condition [16]. 
Moreover, the correct use of biomarkers in INMD allows a specific time- and re-
source-sparing algorithm. In fact, INMD patients, if promptly evaluated through bi-
omarkers, can reach the correct diagnosis earlier and receive consequently an adequate 
management and therapy [17,18]. Occasionally, lab essays are abnormal despite the pa-
tient does not display any clinical sign (e.g., carriers); in these cases, a serum abnormality 
encourages the beginning of a diagnostic workup allowing a prompt genetic counselling 
[10,19]. 
Multiple organs are usually involved in INMD, so that patients are often evaluated 
by multiple clinicians other than expert in NMD before the diagnosis [20,21]. 
In this paper, we present a review of serum biomarkers in INMD to provide a guide 
to address the diagnosis and the correct management. INMD have been classified depend-
ing on the main organ involved (i.e., spinal cord, peripheral nerve, muscle, etc.) and sep-
arately analyzed as neuropathies (axonal and demyelinating), neuromuscular junction’s 
disorders, myopathies (muscular dystrophies, Ion channel myopathies, metabolic myo-
pathies) and hereditary motor neurons diseases. 
2. Muscular Dystrophies 
Muscular dystrophies (MD) constitute a heterogeneous group of INMD with pro-
gressive muscle weakness. Duchenne muscular dystrophy (DMD) is the most common 
and most severe MD and it is characterized by a complete lack of dystrophin due to mu-
tations in the DMD gene [19]. Serum creatine kinase (CK) concentration as well as trans-
minases (Supplementary Materials: Table S1 and Diagram S1) are markedly increased in 
children with DMD prior to the appearance of any clinical sign of disease; increased val-
ues are even observed among newborns [22]. Of interest, the CK peak by age of two years 
is usually from 10 to 20 times the upper normal limit, even if higher values have been 
reported [23]; serum CK progressively fall about 25% per year, eventually reaching the 
normal range in most cases, as the skeleton muscle is replaced by fat and fibrosis. In pa-
tients with Becker muscular dystrophy (BMD), CK concentration is usually elevated 
above five or more times the normal limits [19]. Serum CK is usually modestly elevated 
in limb-girdle muscular dystrophy (LGMD). However, it can be very high in sarcogly-
canopathy, dysferlinopathy, and caveolinopathy [24]. Of interest, in LGMD2L, a condition 
resulting from mutations in ANO5, the gene for anoctamin 5, CK are usually elevated to 
around 1500 to 4500 U/L (range 200–40,000 U/L) and tend to decrease over time [24]. Fur-
thermore, in DMD patients carbonic anhydrase 3 (CAH3), microtubule-associated-pro-
tein-4 and collagen type I-alpha 1 chain concentrations decline constantly over time; of 
interest, myosin light chain 3 (MLC3), electron transfer flavoprotein A (ETFA), troponin 
T, malate dehydrogenase 2 (MDH2), lactate dehydrogenase B and nestin plateaus in early 
teens; ETFA correlates with the score of the 6-min-walking-test, whereas MDH2, MLC3, 
CAH3 and nestin correlate with respiratory capacity [25]. In addition, high serum concen-
trations of a set of muscle-enriched miRNAs, (miR-1, miR-133, miR-206, miR-208b, miR-
208a and miR-499) were significantly elevated in DMD patients compared to healthy sub-
jects[7,18]. 
Serum matrix metalloproteinase-9 (MMP-9) and its inhibitor (TIMP-1) have been pro-
posed as markers of disease progression in DMD [26]. In DMD patients the decrease in 
creatinine and an increase in creatine serum concentrations is likely due to the insufficient 
creatine utilization by muscles. Similar profiles have been observed in other MD such as 
BMD, LGMD2A and LGMD2B. Creatine/creatinine ratio is particularly elevated in the 
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older and more severely affected DMD patients, thus encouraging its use as a marker of 
disease progression. Reduced citrulline concentrations have been found in DMD patients 
[27]. There is a significant increase in fibronectin concentrations in DMD patients com-
pared to age-matched controls, while a similar abnormality is not observable in BMD [28]. 
Patients with myotonic dystrophy type 1 and 2 (DM1 and 2) commonly present mod-
estly elevated serum CK (less than 500 U/L) [29]. Low concentrations of anti-Müllerian 
hormone (AMH) demonstrates decreased ovarian reserve in women with DM1 [30]. Re-
sults of a study in a cohort of DM patients [14] showed a persistent elevation of high sen-
sitivity cardiac troponin T (hs-cTnT) and CK; in contrast, high sensitivity cardiac troponin 
I (hs-cTnI) values were persistently normal throughout the study. In addition, a relevant 
quote of DM patients with cardiac conduction abnormalities and preserved systolic func-
tion presented abnormal NT-proBNP concentration [14]. DM1 patients had insulin-re-
sistance and significantly higher triglycerides (TGs), glucose and Tumor Necrosis Factor 
A; conversely, they had significantly lower concentrations of total serum adiponectin with 
a selective, pronounced decrease of its high molecular weight oligomers [31]. Finally, 
sleep dysfunction, very common in DM1, may be mediated by a dysfunction of the hypo-
thalamic hypocretin because of hypocretin1 reduction in CSF [32]. 
Facioscapulohumeral muscular dystrophy (FSHD), the third most common type of 
MD, is characterized by slowly progressive muscle weakness involving the facial, scapu-
lar, upper arm, lower leg and hip girdle muscles, usually with asymmetric involvement. 
Serum CK can be normal or modestly elevated in FSHD (usually less than five times the 
upper normal limit) [33]. Finally, an elevation of serum muscles (MM) and myocardial 
band (MB) isoforms of CK, as well as carbonic anhydrase III, and troponin I type 2 have a 
minor role to assess the severity and progression of FSHD [8]. 
In Emery-Dreifuss muscular dystrophy (EDMD), a modest elevation of serum CK 
concentration is typical, less than 1000 U/L; an increase up to 20 times the upper normal 
limit sometimes occurs, but it may be seen often higher in the early stages of the disease 
[34]. The concentrations of circulating tenascin-C (TN-C) are elevated in autosomic dom-
inant-EDMD and X-linked-EDMD patients and in some X-linked-EDMD carriers, allow-
ing an identification of EDMD patients at risk of dilated cardiomyopathy[35]. Transform-
ing growth factor beta 2 (TGF b2) and interleukin 17 (IL-17) serum values are consistently 
elevated in EDMD type 2 and LGMD1B patients [36]. 
GNE myopathy, where “GNE” is an abbreviation for the mutated gene (UDP-N-
acetylglucosamine 2-epimerase/N-acetylmannosamine kinase) codifying the key enzyme of si-
alic acid synthesis, is an adult-onset progressive myopathy, in which a mild serum CK 
elevation is reported [37]. The ratio of the Thomsen–Friedenreich (T)-antigen to its si-
alylated form, ST-antigen, detected by liquid chromatography—mass spectrometry and 
liquid chromatography—tandem mass spectrometry (LC-MS/MS), is a robust blood-
based (serum or plasma) biomarker informative for diagnosis and possibly for response 
to therapy for this rare condition [38]. 
3. Metabolic Myopathies 
Metabolic myopathies are INMD in which the pathogenetic mechanism compro-
mises enzymes and proteins involved in intermediary metabolism of glucose and free 
fatty acids [16]. In this review, we focused on glycogenoses, disorders of muscular lipids 
metabolism and mitochondrial myopathies. 
3.1. Glycogenoses 
Muscle glycogenoses constitute a growing number of inborn errors of glycogen metabo-
lism. Deficiencies of virtually all enzymes, which intervene in the synthesis or degradation 
of glycogen, may cause glycogen storage disease (GSD) because of aberrant storage or 
utilization of glycogen [39]. 
In this group McArdle and Pompe disease are the most common conditions [40,41]. 
CK is chronically elevated in nearly all cases of McArdle disease; patients can often show 
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rabdomyolisis and hemoglobinuria after a short-intensity exercise, depicting a very typic 
feature of this disorder [16]. Apart from CK, serum lactate after forearm exercise is another 
simple tool that can be very useful to early recognize this disorder [42]. Patients with the 
most common McArdle disease mutation (R49X) have no protein expressed because of 
nonsense-mediated mRNA decay; consequently, they have a secondary deficiency of pyr-
idoxine (vitamin B6), due to protein-to-protein interaction [16,43]. 
Other metabolic disorders such as Pompe disease (PD) present a less specific pattern 
due to different biochemical pathway involved [44]. HyperCKemia is usually found in 
PD, but the increment of CK is stably high and a muscular stretching impairment is often 
observed mimicking a LGMD [41]; moreover, dried blood spot offers an important tool to 
screen suspected patients for PD [45,46]. 
Further serum biomarkers have a less validated use in clinical practice: some authors 
reported that platelet derived grow factor BB (PDGF-BB) and transforming growth factor 
β1 (TGF-β1) concentrations are significantly lower in PD patients compared to the control 
group and serum; conversely, platelet derived grow factor AA (PDGF-AA) and connec-
tive tissue growth factor (CTGF) values are significantly higher compared to control sam-
ples. Interestingly, PDGF-BB level differs among PD and MD and between symptomatic 
and asymptomatic PD patients [47]. 
In addition, GSD can be associated with hemolysis/hemolytic anemia (e.g., GSD7, 
phosphoglycerate kinase 1 deficiency, GSD12). Finally, many glycogenolytic and glyco-
lytic defects have been also linked to myogenic hyperuricemia, which can lead to gout 
[48]. 
3.2. Disorders of Muscular Lipids Metabolism 
Disorders of muscular lipids metabolism may involve intramyocellular triglyceride 
degradation, carnitine uptake, long-chain fatty acids mitochondrial transport, or fatty acid 
β-oxidation [17]. In these conditions, blood testing for CK, lactate, and glucose is usually 
normal between the episodes of rhabdomyolysis [17]. However, during an acute bout of 
rhabdomyolysis, a significant increase of CK starts within a few hours, during which hy-
perkalemia and hypoketotic hypoglycemia can also occur [17]. Moreover, in more severe 
cases, an acute renal failure can occur with elevations of potassium, creatinine, and urea 
[17]. The acylcarnitine profile, performed by liquid chromatography tandem mass spec-
trometry, is the most sensitive and specific test for a fatty acid oxidation defects [16]. 
Carnitine deficiency (CD) is a potentially lethal but very treatable disorder due to a 
defect in the carnitine organication transporter (OCTN2), resulting in impaired fatty acid 
oxidation [49]. 
CD is clinically characterized by carnitine-responsive acute metabolic decompensa-
tion early in life, or in late onset forms, with skeletal and cardiac myopathy or sudden 
death from arrhythmia [50–52]. 
Hypoglycemia, with minimal or no ketones in urine, and hyperammonemia, with 
variably elevated liver function tests are typical features of this disorder [53]. 
The deficiency of carnitine–palmitoyl-transferase-II (CPT-II, an enzyme involved in 
the transport of fatty acids into the mitochondrial matrix) is clinically characterized by 
recurrent myoglobinuric attacks triggered by exercise, fasting, fever, and infection, which 
may be complicated by acute renal failure and respiratory failure [49]. 
Multiple acyl-CoA dehydrogenation deficiency (MADD) is a disorder of oxidative 
metabolism with a broad range of clinical severity [49]; symptoms and age of onset are 
highly variable and characterized by muscle involvement (myalgia and weakness recur-
rent episodes of lethargy, vomiting, hypoglycemia, metabolic acidosis, and hepatomeg-
aly) [54]. 
The diagnosis is suggested by the acyl-carnitine profile and urinary organic acids, 
revealing low serum free carnitine but elevated acyl-carnitines [49]. 
Neutral lipid storage disease with myopathy (NLSD-M), increased CK concentra-
tions, cardiomyopathy, diabetes mellitus, hepatic steatosis, and hypertriglyceridemia. 
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Leukocytes show a characteristic accumulation in cytoplasm of triglycerides called “Jor-
dan’s anomaly” [49]. 
3.3. Mitochondrial Myopathies 
Mitochondrial myopathies (MM) are disorders with mitochondrial function impair-
ment, which usually present multisystem features and, sometimes specifical biomarkers 
have been recognized [55]. 
Elevated serum basal lactate have a sensitivity of approximately 65% and specificity 
of 90% [56], the abnormal lactate value is more evident after aerobic exercise test, an im-
portant tool in the clinical suspected of MM [55]. 
Serum CK is often normal in MM, but it might result elevated after rhabdomyolysis 
and in a minority of patients [55]. CK concentrations continually higher than three times 
the normal upper limit should arise a prompt consideration of a different diagnosis [16]. 
About 50% of patients with Mitochondrial encephalopathy with lactic acidosis and 
stroke-like episodes (MELAS) can manifest with type 2 diabetes mellitus or impaired oral 
glucose tolerance [16,57,58]. Plasma amino acid testing can reveal elevated alanine, espe-
cially after aerobic exercise. Urine organic acid analysis may reveal high 3-methylgluta-
conic acid or the tricarboxylic acid intermediates (fumarate, malate, citrate) [16]. Increased 
CSF proteins, lactic acidemia and hyperalaninemia are also common in mitochondrial 
neurogastrointestinal encephalopathy [59], an autosomal recessive condition due to mu-
tations in the gene specifying thymidine phosphorylase with progressive gastrointestinal 
symptoms and muscle involvement [60]. The diagnosis is based on the detection of path-
ogenic mutation, reduction of thymidine phosphorylase enzyme activity or elevated plas-
matic thymidine and deoxyuridine. 
Cycle ergometry exercise testing in mitochondrial myopathies might demonstrate a 
low the maximum oxygen consumption a high respiratory exchange ratio (indicative of 
early lactate production), or both [16]. Moreover, the oxidative stress have a relevant path-
ogenic role in MM; hence, oxidative stress markers, such as advanced oxidation protein 
products have been successfully tested in MM [61]. 
4. Ion Channel Myopathies 
Ion channel myopathies (ICM) include various rare INMD due to mutations in genes 
encoding ion channels Main disorders of this group are periodic paralyses (PP) and non-
dystrophic myotonias (NDM) [62]. 
The diagnosis of such myopathies relies on the patient’s personal and familial medi-
cal history and several laboratory findings, with genetic studies representing the diagnos-
tic mainstay. 
As far as hypo- and hyperkaliemic periodic paralyses (PP) are concerned, serum di-
agnostic supportive criteria are constituted by K+ concentrations <3.5 and >4.5 mEq/L dur-
ing weakness attacks, respectively [63–73]. Raised CK may be present too [74,75]. Moreo-
ver, thyroid function tests may be useful to distinguish HypoPP from thyrotoxic paralysis 
[76,77], because of HypoPP is reported as a rare complication of hypertyroidisim [78]. 
CK elevation is common in myotonia congenita [75,79–87] and may be present in 
paramyotonia congenita [88]. Inherited susceptibility to malignant hyperthermia syn-
drome (MHS) occurs in patients exposed to anesthetic agents causing increased body tem-
perature, muscle rigidity or spasms, rhabdomyolysis, tachycardia, and other life-threat-
ening symptoms [89]. Mutations in the ryanodine receptor RYR1, CACNA1S or STAC3 
genes are encountered in MHS, resulting in excessive cytoplasmic calcium accumulation 
in response to both pharmacological and non-pharmacological triggers. As a result, pa-
tients experience recurrent episodes of hyperCKemia and rhabdomyolysis [11,89,90]. 
RYR1-related central core myopathy usually shows elevation of CK [91–94], and, in some 
cases, it can be also normal [95], AST, ALT and γGT may be elevated or normal [93,96]. 
5. Congenital Myasthenic Syndromes 
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Congenital myasthenic syndromes (CMS) refer to a heterogenic group of inherited 
neuromuscular transmission disorders (NTD) with exercise intolerance and muscular 
weakness [97]. There are no relevant biomarkers for CMS and the diagnosis is usually 
achieved through neurophysiology [97]. Indeed, CK concentrations are usually normal in 
CMS [97], but there are reported cases in which CK and aldolase concentrations can be 
mildly elevated [98,99]. In these cases, elevated CK is due to a phenomenon called end-
plate myopathy [99]. Circulating miRNAs [100] and plasmatic titin [101] have been pro-
posed as possible biomarkers for autoimmune Myasthenia Gravis, but their role has not 
been explored yet in inherited CMS. 
6. Motor Neurons Diseases 
6.1. Spinal Muscular Atrophy 
Spinal muscular atrophy (SMA) is characterized by motor neuron degeneration and 
progressive muscle atrophy and weakness caused by mutation of the survival motor neu-
ron (SMN) genes. After neuronal degeneration or axonal injury specific cytoskeletal pro-
teins of the neurons, including neurofilaments (NF), are released in the extracellular space, 
in Cerebrospinal fluid (CSF) and in the blood; about 80% of NF are phosphorylated (pNF) 
conferring more resistance in the serum. Several studies explored the role of NF as a bi-
omarker of disease severity and progression. There are three different NF type distin-
guished by molecular weight: light (NF-L), medium and heavy (NF-H). High concentra-
tions of NF-H have been detected in blood of amyotrophic lateral sclerosis, SMA, Alz-
heimer’s disease, Parkinson disease and multiple sclerosis [102–107]. 
Plasma phosphorylated neurofilament heavy chain (pNF-H) in infants with SMA are 
about 10-fold higher than age-matched infants without SMA. Treatment with nusinersen 
(the first approved treatment for SMA favoring expression of normal SMN protein) in-
duce a faster decline in pNF-H concentrations at two and ten months than sham con-
trolled-treated infants, followed by a relative stabilization [108]. These data suggest NF as 
a promising biomarker for SMA severity and response to treatment. 
Patients with SMA have been shown to have lower values of creatinine compared to 
age-matched controls [109]. In the skeletal muscles is stored most creatine of the body, 
and its metabolism is essential to maintain the muscle function; creatinine is a product of 
muscle creatine metabolism. Chronic medical conditions associated with cachexia (and 
muscle hypotrophy) could be associated with lower concentrations of creatinine. A recent 
study [109] showed significant differences of creatinine concentrations depending on the 
SMA subtype (with SMA 3 > SMA 2 > SMA 1 concentrations) and on clinical severity; 
furthermore, a positive association of serum creatinine concentrations and the number of 
SMN2 gene copies has been documented; a positive association of creatinine concentra-
tions was also related to denervation signs expressed by maximal compound muscle ac-
tion potential amplitude evoked by distal stimulation of ulnar nerve, and to the motor 
unit number estimation. Considering that the muscle atrophy could be considered a con-
founding factor for low creatinine concentrations, all the reported associations with the 
severity of disease, still resulted statistically significant, after correction for lean mass 
[109]. 
6.2. Amyotrophic Lateral Sclerosis 
Amyotrophic lateral sclerosis (ALS) causes upper and lower motor neuron degener-
ation, with progressive paresis of arms, legs and bulbar muscles finally resulting in death 
for respiratory failure. 
Most ALS cases are sporadic and only about 10% are familiar as associated to various 
specific gene mutations (e.g., SOD1, TDB-43, FUS, DPRs, etc.). 
Even if an aspecific marker serum CK is reported in an high percentage of ALS pa-
tients [110],markers of inflammation [111,112] as well as creatinine [113] have a prognostic 
role in ALS. 
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The most studied biomarker for SLA is the pNF-H which show increased concentra-
tions both in CSF (sensitivity 71%, specificity 88%) [114] and in the blood (sensitivity 58%, 
specificity 89%) [115]. As showed in SMA and other neurodegenerative diseases, the ax-
onal injury induces the release of these cytoskeletal proteins in the extracellular space, CSF 
and blood. However, this measure is not specific for familiar ALS respect to sporadic 
forms and it is not statistically different in Riluzole-treated vs. non-treated patients [115]. 
By the way, NF still represent a possible marker for upcoming therapies. 
Testing the hypothesis of ALS as an autoimmune pathology, neuron glycolipids such 
as sulfoglucuronosyl paragloboside (SGPG), target of various neuropathies, have been ex-
plored in ALS and anti-SGPG were found in the sera of 13,3% ALS patients [116]. 
Other biological markers of ALS remain of uncertain significance in the pathobiology 
of disease, but include transthyretin, complement C3 protein and fetuin-A [117–119]. 
7. Axonal Neuropathies 
This group includes disorders in which polyneuropathy (sensory-motor deficit asso-
ciated with reduced jerks in the distribution of the main peripheral nerves) is the main 
feature and disorders with nerve involvement as part of multisystemic disease. 
7.1. Charcot–Marie–Tooth 2 (CMT2) 
Charcot–Marie–Tooth (CMT) is an autosomal dominant inherited motor and sensory 
neuropathy, characterized by peripheral nerve damage and classically described in CMT 
Type 1 and 2 depending on the neurophysiological features [120]. CMT2 is genetically 
heterogeneous and exists in several different subtypes (e.g., CMT2A, CMT2B, CMT2E, 
etc.) [20]. CMT2 is an axonal form of the disease in which the loss of axons reduces muscle 
innervations [120]. Neurofilament light chain (NfL) represent a possible biomarker of ax-
onal damage in CMT2 correlating with disease severity [121]. 
7.2. Multisystemic Diseases 
The term “amyloidosis” gathers several diseases associated with deposits of amyloid 
fibrils involving peripheral and autonomic nervous systems; among them about 10% is 
represented by inherited forms (hereditary amyloidosis, HA) [122]. HA includes Heredi-
tary amyloidogenic transthyretin (hATTRv) [123], amyloidosis derived from a fibrinogen 
variant (AFib), that is the most frequent HA in Northern Europe [124], variants of apolipo-
proteins (AI, AII, C-II, CIII), gelsolin (AGel), and lysozyme (ALys) [125]. 
In a study on hATTR, serum retinol-binding protein 4 (RBP4) concentration was 
lower in patients with hATTR V122I amyloidosis; also a lower concentration of B-type 
natriuretic peptide (BNP) and transtiretin (TTR), as well as, a higher concentration of Tro-
ponin I (TrI) and hematocrit have been reported [126]. Increased serum concentrations of 
amino-terminal prohormone of brain natriuretic peptide (NT-proBNP) and Troponin T 
(TrT) are the mainstay in patients with polineurophaty compared to TTRv carriers and 
healthy subjects [127]. Of interest, serum neurofilament light chain (NfL) concentrations 
correlated with Troponin T in all patient groups, but not with NT-proBNP. Furthermore, 
higher cytokine concentrations (TNF-α, IL-1β, IL-8, IL-33, IFN-β, IL-10 and IL-12) have 
been reported in hATTR patients. In ATTRv [128]. Many study described elevated NfL 
also in early stage of hATTR, showing a correlation with the severity of polyneuropathy, 
thus proposing NfL as a diagnostic and prognostic biomarker [10,129,130]. A further 
study confirmed the importance of NfL as a biomarker for nerve damage showing a sig-
nificant decrease after therapy with Patisiran [131]. 
Ataxia with oculomotor apraxia is a group of recessive ataxias: ataxia-telangectasia 
(AT), ataxia with oculomotor apraxia type 1 (AOA1) and type 2 (AOA2). All these condi-
tions share axonal neuropathy and elevated serum a.lpha-fetoprotein (AFP) [132]. AOA1 
is an autosomal recessive disease due to mutations in the APTX gene, which encodes for 
aprataxin. During the course of AOA1, decreased serum albumin and increased serum 
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total cholesterol can be seen [13,133]. In addition, hypoalbuminemia, hypercholesterole-
mia and increased serum creatine kinase (CK) were reported in association with increased 
AFP [134]. However, according to another study hypoalbuminemia and hypercholester-
olemia with normal AFP are the hallmarks of AOA1 [135]. AOA2 is caused by mutations 
in the SETX gene, encoding for a DNA/RNA helicase protein [136]. Elevation of AFP is 
present in 99% of cases and is stable over the course of disease, but it usually do not cor-
relate with disease severity [137]; elevated CK, mild hypoalbuminemia, or hypercholes-
terolemia can also be present in AOA2 patients [138]. Ataxia-telengectasia (AT) is caused 
by mutation in the ATM gene, that encodes a phosphatidylinositol-3 kinase protein (PI3K). 
Immunoglobulins (Ig) lare usually reduced in AT and elevation of AFP is progres-
sive[138]. Conversely, in A-TLD, a rare form caused by mutations in the hMRE11 gene, 
patients have normal AFP serum concentrations [132,139]. 
Spinocerebellar ataxias (SCA) are a heterogenous group of diseases with CAG-trinu-
cleotide expansions. Axonal polyneuropathy in SCA is one of the typical clinical features 
and depends on neuronal loss for inactivation of repair pathways [140]. Peripheral axonal 
neuropathy, tested by electrophysiology, is consistent among SCA1, 2, 3, 18, 25, 38, 43, 46 
and specially SCA4 [5,141]. Neurofilament light polypeptide (NfL) is marker of neuronal 
damage. Serum concentrations of NfL are increased in patients with SCA, but the results 
have not already been validated [140,142]. 
Hereditary spastic paraplegias (HSP) are inherited neurodegenerative diseases, char-
acterized by lower limbs weakness and spasticity [143]. Axonal neuropathy is frequent in 
SPG7, SPG11, and SPG15 and less commonly in SPG3A, SPG4, and SPG5 [143]. SPG5, a 
rare form of HSP, is caused by recessive mutation in the CYP7B1 gene, encoding oxysterol-
7α-hydroxylase [144]. CYP7B1 substrates, including 27-hydroxycholesterol (27-OHC), 
have been described cerebrospinal fluid (CSF) and in the sera of SPG5 patients; the latter 
were correlated with severity and duration of the disease [145]. 
Interestingly, serum 25-OHC and 27-OHC, have been validated as diagnostic bi-
omarkers in SPG5 and it has been proved that atorvastatin can decrease serum 27-OHC 
by ∼30% [146]. 
Hepatic porphyrias (HP) are metabolic disorders of the heme metabolism; HP are 
caused by accumulation of heme intermediates due to enzymatic alteration in the heme 
biosynthesis pathway [147]. Acute intermittent porphyrias (AIP) is the most common sub-
type of HP and presents an autosomal dominant inherited pathology characterized by 
accumulation of porphyrin precursors, porphobilinogen (PBG) due to inherited deficiency 
of porphobilinogen deaminase [148]. Variegate porphyria (VP) is caused by deficiency of 
protoporphyrinogen oxidase (PPOX) that causes accumulation of δ -aminolevulinic acid 
(ALA) [147,148]. Porphyric attacks can be characterized by peripheral neuropathy, typi-
cally a motor neuropathy with symmetrical proximal muscle weakness [149]. Increased 
urinary porphobilinogen (PBG) and δ-aminolaevulinic acid (ALA) concentrations are usu-
ally detected during acute attacks, with normal interictal ranges; it has been reported that 
raised concentrations persist for many years in AIP patients [150]. 
GM2 gangliosidosis comprises Tay-Sachs disease, Sandhoff disease and GM2 gangli-
osidosis AB due to β-hexosaminidase A, β-hexosaminidase A+B and GM2 activator defi-
ciency respectively. Several serums (i.e., lactic dehydrogenase malic dehydrogenase, fruc-
tose 1,6-diphosphate aldolase) and liquoral biomarkers (i.e., epithelial-derived neutrophil 
activating protein 78, monocyte chemotactic protein 1, macrophage inflammatory protein-
1 alpha, macrophage inflammatory protein-1 beta, tumor necrosis factor receptor 2) were 
identified in gangliosidosis affected patients [151]. A recent study proposed serum aspar-
tate transaminase (AST) as new potentially biomarker for gangliosidosis [151]. 
X-linked adrenoleukodystrophy (XALD) is the most common peroxisomal disorder 
due to mutations of the ABCD1 gene leading to very long-chain fatty acids (VLCFA) ac-
cumulation in blood and a variety of tissue [152]. In males with clinical suspicion, the 
diagnosis of XALD is allowed by elevated serum or plasma concentrations of hexacosa-
noic acid C26:0 and high ratio C24:0/C22:0 and C26:0/C22:0 [152]. An alternative and more 
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accurate biomarker to detect the elevated serum VLCFA is the use of 1-hexacosanosyl-2-
lyso-sn- 3-glycero-phosphatidylcholine (26:0-lyso-PC) in DBS and it could be useful for 
newborn screening and diagnosis in women [153]. A recent study suggests new optimized 
cutoff values for both ratios C24:0/C22:0 and C26:0/C22:0, in combination with standard 
lipid profile considered that low-density lipid concentrations strongly correlate to all 
VLCFA [9]. 
Fabry disease (FD) is an X-linked inborn error of glycosphingolipid catabolism due 
to deficiency of α-galactosidase A (α-Gal A) leading accumulation of globotriaosylcer-
amide in body fluids and lysosomes of vascular endothelium [154]. The diagnostic algo-
rithm in FD is gender-specific indeed the measurement of blood α-Gal A activity is rec-
ommended in males, and optionally in females. Globotriaosysphingosine for identifica-
tion of atypical FD variants and high- sensitive troponin T for identification of cardiac 
involvement are also important diagnostic biomarkers [6]. 
8. Demyelinating Neuropathies 
Among this group of disorders, we report demyelinating CMT and inborn errors of 
metabolism. 
8.1. Charcot–Marie–Tooth Spectrum Disorders 
In the actual scenario there are no validated blood or liquoral biomarkers for CMT 
spectrum disorders, although a recent observational study suggested potentially new di-
agnostic and prognostic biomarkers in CMT1A patients [155]; indeed, the upregulation of 
the protein and lipid catabolism products plasma concentrations (i.e., dipeptide glutami-
nyl-serine, tryptophan, urobilinogen, polyamine acetylagmatine, sphingosine-1-phos-
phate, 6-hydroxysphingosine, lysophosphatidylcholine, 11-hydroxyeicosatetraenoate 
glyceryl ester) and downregulation of leucine plasma concentrations have been reported 
[155]. A more recent cross-sectional study showed the higher concentration of plasma 
neurofilament light chain in CMT patients correlating with disease severity [121]. In ad-
dition, it has been documented that some CMT1A patients can display serum PMP22 an-
tibody and CSF protein content moderately elevated [156]. 
8.2. Inborn Errors of Metabolism 
Inborn errors of metabolism (IEMs) are genetic disorders that cause disruption of a 
metabolic pathway leading to the accumulation of a toxic substrate [157]. IEMs may pre-
sent as an apparently isolated peripheral neuropathy at any age or a polyneuropathy may 
be the only part of the clinical picture. 
Refsum disease is an inborn error of lipid metabolism due to low phytanoyl-CoA 
hydroxylase activity leading to high phytanic acid plasma concentrations which repre-
sents the pathognomonic biomarker [158]. A relapsing-remitting polyneuropathy is the 
main feature with acute exacerbation in the setting of elevated phytanic acid blood con-
centrations caused by high phytanic acid intake, weight loss or pregnancy with elevated 
CSF protein concentration [159]. 
Tangier disease (TD) is an inherited lipid trafficking disorder characterized by severe 
deficiency or absence of high-density lipoprotein (HDL) in the circulation resulting in tis-
sue accumulation of cholesteryl esters, particularly in the reticuloendothelial system with 
hyperplastic yellow-orange tonsil and hepatosplenomegaly [160]. As the high clinical sus-
picion, serum hypertriglyceridemia, very low HDL cholesterol and undetectable apolipo-
protein A1 are pathognomonic for TD [161]. 
Metachromatic leukodystrophy (MLD) is caused by deficiency of lysosomal aryl-
sulfatase A with cerebroside deficiency and sulfatides accumulation in various tissues. 
The diagnosis of MLD is confirmed by demonstrating deficient ASA activity in leukocytes 
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and increased urinary sulfatide concentrations [162]. Some authors documented eleva-
tions of proinflammatory cytokines (e.g., IL8, IL-1Ra) and vascular endothelial growth 
factor in both CSF and plasma of MLD patients [163]. 
Krabbe disease (KD), also known as globoid cell leukodystrophy, is a rare lysosomal 
storage disorder caused by deficiency of galactocerebrosidase (GALC) leading to genera-
tion of psychosine, a cytotoxic agent that causes loss of oligodendrocytes and Schwann 
cells [164]. Newborn screenings are available for Krabbe disease with measurement of 
GALC enzymatic activity in DBS and measurement of psychosine in DBS as second-tier 
test may help to differentiate infantile from late-onset KD variants, as well as from GALC 
variant and pseudodeficiency carriers [165]. Psychosine concentrations have also been 
evaluated as biomarker to predict the severity of disease considering patients with psy-
chosine greater concentrations at high risk to develop early-onset KD [166]. 
Zellweger spectrum disorders are caused by mutation in one of 13 different PEX 
genes resulting in different clinical phenotypes [167]. The higher plasma concentrations 
of very long-chain fatty acids (e.g., C26:0 lysophosphatidylcholine), polyunsaturated fatty 
acids, bile acid intermediates (i.e., di- and trihydroxycholestanoic acid), phytanic acid, 
pristanic acid, pipecolic acid and detectable urinary concentrations of bile acid intermedi-
ates or detectable pipecolic, glycolic, and oxalic acid may support the diagnosis [168]. 
Niemann–Pick disease is an autosomal recessive lipid storage disorder that com-
prises types A (NP-A) and B (NP-B) caused by deficiency of acid sphingomyelinase and 
type C (NP-C) caused by protein NPC1 defect leading to intracellular sphingomyelin and 
free cholesterol accumulation respectively. Reduced sphingomyelinase activity in circu-
lating leukocytes, elevated both triglycerides and serum LDL-cholesterol and reduced 
HDL-cholesterol serum concentrations are the diagnostic hallmarks of the NP-B [169]. 
Cholesterol oxidation products such as 3β,5α,6β-triol and 7-ketocholesterol (7-KC) might 
represent a specific and sensitive blood-based biomarker for NP-C [170]. A further study 
identified two secreted proteins (i.e., galectin-3, cathepsin D) with increased serum con-
centrations in NPC1 patients correlating with disease severity [171]. Additionally, a recent 
study showed significantly decreased values of HSP70 in individuals with NP-C [172]. 
The combination of 7-KC, lysosphingomyelin and bile acid-408 improves the accuracy of 
NP-C diagnosis [173]. 
Abetalipoproteinemia typically presents in infancy with failure to thrive and malab-
sorption of fat and fat-soluble vitamins leading to multiorgan and neuromuscular in-
volvement with cranial and peripheral nerve demyelination due to vitamin E deficiency. 
Common serums findings are extremely low LDL-cholesterol, triglyceride and apoB con-
centrations [174]. 
Beta-Mannosidosis is a lysosomal storage disease due to an isolated deficiency of the 
enzyme betas-mannosidase with various degrees of neurological deterioration. The diag-
nosis is supported by reduced enzyme activity in plasma and leukocyte [175]. Liquid chro-
matography-tandem mass spectrometry (UPLC-MS/MS) for urinary free oligosaccharides 
is a useful diagnostic tool [176]. 
Type 1 hyperoxaluria (PH1) is a rare autosomal recessive disease due to mutation in 
the alanine-glyoxalate aminotransferase gene leading to glyoxylate accumulation and its con-
version to oxalate with calcium oxalate crystals deposition in various tissues [177]. The 
biochemical hallmarks of PH1 are hyperoxaluria with or without hyperglycolaturia; 
hence, 24 h urine collection measuring oxalate, creatinine and glycolate is recommended. 
Plasma oxalate concentrations are also useful in patients with renal failure, whereas 
higher ones are helpful to the diagnosis [12]. 
Tyrosinaemia type 1 (HT1) is a rare autosomal recessive disorder of amino acid me-
tabolism resulting from fumarylacetoacetase 1 deficiency. The diagnosis is supported by 
increased plasma concentrations of tyrosine, methionine and phenylalanine, increased 
concentrations of hepatic transaminases and plasma alfa- fetoprotein [178]. As hypertyro-
sinemia is caused by other conditions, the diagnosis is allowed by the identification of the 
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pathognomonic and more sensitive and specific biomarker succinylacetone on blood or 
urine with different cut-off reported [179,180]. 
Methylmalonic aciduria and homocystinuria cblC type are the most frequent inborn 
error of vitamin B12 metabolism. The biochemical hallmarks are elevated plasma and 
urine concentrations of methylmalonic acid, cystathionine and homocysteine with hypo-
methioninemia, whereas metabolic acidosis and hyperammonemia have been rarely re-
ported [181]. 
Cerebrotendinous xanthomatosis (CTX) is an autosomal recessive inborn lipid stor-
age disorder due to enzyme sterol 27-hydroxylase deficiency resulting in impaired bile 
primary acid synthesis, increased concentration of bile alcohols and increased accumula-
tion of both cholestanol and cholesterol in plasma and in various tissues, particularly in 
the nervous system [182]. High plasmatic concentrations of cholestanol in the presence of 
normal or low plasma concentrations of cholesterol, decreased chenodeoxycholic acid and 
increased concentration of bile alcohols are the laboratoristic hallmark of CTX [183]. 
9. Conclusions 
Neuromuscular disorders can be very complex with the involvement of various or-
gans and systems. A number of biomarkers are to date available to support the diagnosis 
of INMD, but the role of expert clinician is crucial. Some markers are commonly altered 
in many conditions in similar way in different disorders, so that the physical examination 
should be the first step to raise the clinical suspicion. The complete neuromuscular exam-
ination, followed by subsequent evaluations is the easiest way to obtain diagnoses to date. 
On the other hand, some biomarkers are associated with specific disorders and their 
recognition can be crucial for the diagnosis. Indeed, it is not unusual to see clinicians who 
are not familiar with rare diseases facing with INMD, because of the very broad range of 
serum and urinary alterations encountered in clinical practice. Hence, the complete 
knowledge of such abnormalities can accelerate the diagnostic workup supporting the 
referral to specialists in neuromuscular disorders. 
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